Stocks / NASDAQ / Contineum Therapeutics Inc.

Contineum Therapeutics Inc.

Industry: Health Care – Biotechnology: Pharmaceutical Preparations

Stock Symbol: CTNM – NASDAQ

Animal Usage: Animal Testing

Our Opinion

Contineum Therapeutics Inc. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.

Supporting Evidence:

The company confirms in the following report that they exploit animals for product testing.

“Using genetic knockout animals, studies demonstrated that this response was driven by activation of the LPA1R. In further studies, rodents lacking the LPA1R were protected from bleomycin-induced pulmonary fibrosis, one of the key animal models for IPF, by reducing fibroblast recruitment and vascular leak, as shown in the figure below. Subsequent studies have replicated these findings using small molecule LPA1R selective antagonists.” (Page 118) Read the full document

Company Description

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.

Company Website: https://contineum-tx.com

Contact: ir@contineum-tx.com